Corvus Pharmaceuticals to Present Data on Lead Checkpoint Inhibitor CPI-444 in Renal and Lung Cancer at 2017 ASCO Annual Meeting

BURLINGAME, Calif., May 15, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that it will present an oral abstract presentation at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6 in Chicago, Illinois. The abstract for the presentation will be available on the ASCO website on May 17 at 5:00 p.m. ET.  Following are details for the oral presentation.

Oral Presentation

Abstract #: 3004
Title: Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients
Presenter: Lawrence Fong, M.D., Leader, Cancer Immunotherapy Program, Co-Director, Parker Institute of Cancer Immunotherapy at University of California, San Francisco
Presentation Date and Time: Monday, June 5, 2:27 p.m. CT
Location: Hall D1

About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule and antibody agents that target the immune system to treat patients with cancer. These agents block or modify crucial immune checkpoints and reprogram immune T-cells. Corvus’ lead product, CPI-444, is a checkpoint inhibitor that is designed to disable a tumor’s ability to subvert attack by the immune system by inhibiting adenosine in the tumor microenvironment. CPI-444 is a small molecule that is taken orally. CPI-444 is currently being evaluated in a multicenter Phase 1/1b clinical trial in patients with various solid tumors. This successive expansion cohort trial is examining the activity of CPI-444 both as a single agent and in combination with Genentech’s Tecentriq® (atezolizumab), an anti-PD-L1 antibody. Corvus is conducting the trial with Genentech, a member of the Roche Group, under a clinical trial collaboration the two companies entered into in October 2015. For more information, visit

Tecentriq® is a registered trademark of Genentech.

CONTACT: Corvus Contact:
Jason Coloma
SVP, Chief Business Officer  
Corvus Pharmaceuticals, Inc. 

Media Contact:
Julie Normart
Pure Communications